ERBB2 and gastric cancer: Due to the dynamic and unstable nature of cancer’s genome, as well as intratumoral heterogeneity, and inevitable clonal evolution, change of HER2 status may not be uncommon in gastric cancer and likely contributes as a major mechanism of acquired resistance to anti-HER2 treatment.